Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy.
Abiraterone acetate will still need approval from the European Commission before it can actually be prescribed in the EU nations, but such approval usually occurs within a few months of a decision by EMEA. And of course an approval will still be followed by country-specific negotiations about the cost of abiraterone acetate before it can actually be covered under the national health systems of nations like the UK and Germany.
Filed under: Drugs in development, Management, Treatment Tagged: | abiraterone, approval, Europe, Zytiga
Leave a Reply